Gastric cancer (GC) is one of the most frequent malignant tumors worldwide and is associated with high invasiveness, high metastasis and poor prognosis. Cancer-associated fibroblasts (CAFs), residing around tumor cells in tumor stroma, are important modifiers of tumor initiation and progression. However, the molecular mechanisms by which CAF's modulate tumor development have yet not to be characterized in GC. Here we performed tissue assay analyses identifying that Lumican, an extracellular matrix protein, is highly expressed in human gastric CAFs and its expression is positively associated with depth of invasion, lymph node metastasis, TNM stage and poor survival rate of GC. Functional studies revealed that integrin b1-FAK signaling pathways mediate the promoting effect of Lumican on GC cell proliferation, migration and invasion in vitro. In accordance with these observations, in GC cells co-cultured with CAFs in which Lumican had been knocked down, decreased gastric tumor growth and metastasis in vivo was apparent. In summary, CAF-derived Lumican contributes to tumorigenesis and metastasis of GC by activating the integrin b1-FAK signaling pathway.
Gastric cancer (GC) is one of the most frequent malignant carcinoma worldwide. Despite the improvement in surgical techniques and adjuvant therapy, 1, 2 GC is still the second leading cause of cancer-related deaths, 3, 4 with a 5-year overall survival of < 25%. 5 The high mortality in patients with GC is mainly ascribed to recurrence and metastasis. Even in early GC, the incidence of lymph node metastasis exceeds 10%. 6, 7 Understanding the molecular and cellular mechanisms underlying GC metastasis will assist in the process of identification of useful biomarkers as well as more effective molecular-targeted treatments. Tumor metastasis is not only closely correlated with the properties of tumor cells, but also with tumor stroma, 8 which is composed of fibroblasts, extracellular matrix proteins, endothelial cells and lymphocytic infiltrates. Interactions between tumor and tumor stroma affect tumor growth, invasion and metastasis. Cancer-associated fibroblasts (CAFs) are the major stromal cells and are distinguishable from other cells by their spindle-shape morphology and expression of markers including fibroblast activation protein alpha (FAP-a) and alpha smooth muscle actin (a-SMA). 9, 10 CAFs actively communicate with cancer cells, and in many solid tumors contribute to tumor progression through secretion of growth factors, hormones and cytokines. [11] [12] [13] Our previous studies have demonstrated that the crosstalk between GC cells and stromal CAFs contributes to tumor growth through hepatocyte growth factor (HGF) signaling. Although it has been shown that CAFs are important modifiers of tumor progression, the mechanisms underlying their promotion of tumor metastasis remain largely unknown in GC. 14 Lumican is an extracellular protein belonging to the family of small leucine-rich repeat proteoglycans (SLRPs). breast cancer, a high expression level of Lumican in the stromal tissue is associated with a high tumor grade, low estrogen receptor expression and young age. 19 But in melanoma, Lumican inhibits the development of melanoma and functions as a tumor suppress gene. 20 The abnormal expression of Lumican in tumor tissues suggests that Lumican may play a role in cancer pathogenesis and progression, but the specific mechanism of Lumican's support of tumor progression in GC has not been fully elucidated.
Here we measured Lumican expression in human GC and explored the role and underlying mechanisms of stromal Lumican with respect to GC progression in vitro and in vivo models. Lumican expression was elevated in gastric CAFs and expression was positively associated with depth of invasion, lymph node metastasis and late TNM stage. In addition, knockdown of Lumican in CAFs impaired the GC cell proliferation, migration and invasion in vitro, as well as tumorigenesis and peritoneal metastasis in vivo. Further functional studies revealed that integrin b1-FAK signaling pathway mediated the effect of stromal Lumican on GC cell metastasis potential. Thus, these data collectively indicate that stromal Lumican is involved in GC initiation and progression. Targeting stromal Lumican may provide a potential treatment strategy for GC.
Material and Methods

Tissue specimens
GC tissues and adjacent non-tumor tissues were collected from 117 patients, who received no chemotherapy or radiotherapy, between 2010 and 2013 at the Ruijin Hospital, Shanghai, China. The study was approved by the Ethics Committee of Ruijin Hospital, Shanghai Jiaotong University, School of Medicine, and all patients provided written informed consent prior to this study. All the patients include 84 men and 33 women, the average age of who is 61.6 years old. All the tissues samples were confirmed by two clinical pathologists and the tumor TNM stage was defined according to the UICC TNM classification.
Cell lines
GC cell line MKN45 was purchased from Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences and were cultured at 378C in a humidified cell incubator with 5% CO2 with RPMI-1640 medium containing 10% calf serum with 100 U/mL penicillin and 100 lg/mL streptomycin. The cell line was authenticated by STR/DNA profiling by HKGENE (Beijing, China). Cancer-associated fibroblasts (CAFs) and adjacent normal fibroblasts (NFs) were isolated from freshly resected tissues from GC patients at the Department of Surgery, Ruijin hospital, Shanghai Jiaotong University, school of Medicine. Tumor tissues and adjacent nontumor tissues apart from the margin of tumor resection at least over 5 cm were mechanically minced into small pieces (1-1.5 mm 3 ) and seeded onto 10 cm petri dishes in Dulbecco's modified Eagle's medium (DMEM) with 10% FBS, 100 U/mL penicillin and 100 lg/mL streptomycin. After 7-14 days of culture, there would produce a homogeneous group of fibroblasts in the dishes under these conditions. In order to minimize clonal selection and culture stress, we passaged the fibroblasts for >10 times and then used for subsequent experiments. In addition, we also took identification test for harvested fibroblasts by flow cytometry using fluorosceinisothiocyanate (FITC)-conjugated anti-human a-smooth muscle a-actin antibody.
Immunofluorescence
Frozen tissue sections from GC were fixed with 4% paraformaldehyde for 15 min at room temperature and washed with phosphate buffered saline (PBS). The sections were permeabilized with 0.5% Triton X-100 and blocked with 5% BSA for 1 hr prior to incubation with primary antibodies including anti-a-SMA, anti-nucleus DAPI and anti-Lumican (Abcam, dilution 1:200) at 378C for 2-3 hrs. After 3-5 rinses with PBS, the sections were incubated with fluorescent secondary antibody for 1 hr. Then we acquired images by a fluorescence microscope for the following analysis.
Immunohistochemistry (IHC)
GC tissue samples were first formalin-fixed and paraffinembedded, then dewaxed in xylene, rehydrated with gradient ethanol and treated in 0.01 mol/L citrate buffer (pH 6.0) for antigen retrieval. Then samples were stained with rabbit antiLumcian monoclonal antibody (Abcam, dilution 1:150) at 48C overnight, followed by incubation in secondary biotinylated anti-rabbit antibody for 30 min at 378C, and finally visualized with DAB solution and counterstained with hematoxylin. Each stained sample was evaluated by two senior pathologists unaware of the clinical information, with conflicting cases adjudicated by a third pathologist. Five sights were selected typically and observed with a light microscope What's new? Cancer-associated fibroblasts (CAFs) can promote tumor progression and metastasis in gastric cancer (GC). However, the molecular mechanisms by which CAFs modulate tumor development are not well understood. In this study, the authors found that the extracellular-matrix protein Lumican is highly expressed by CAFs in GC. This, in turn, activates the integrin b17FAK signaling pathway, which leads to increased tumor-cell proliferation, migration and poor prognosis. Lumican may thus offer a potential therapeutic target in GC.
for the immunohistochemistry. The score of positive cell percentage were classified by four grades (percentage): 0 (<10%), 1 (10%-30%), 2 (30-50%) and 3 (> 50%). The score of staining intensity were also divided into four grades (intensity): 0 (no staining), 1 (weak staining), 2 (moderate staining) and 3 (strong staining). IHC total score 5 positive cell score 1 staining intensity score. The overall scores 0, 1-2, 3-4 and 5-6 was defined as negative (-), weak positive (6), moderate positive (1) and strong positive (11), respectively.
Quantitative real-time PCR (qRT-PCR)
Total RNA from cells and tissues was extracted using Trizol reagent (Invitrogen, Carlsbad, CA) and cDNA was synthesized with Reverse Transcription system (Promega, Madison, WI) according to the manufacturer's instructions. QRT-PCR was performed to quantify the mRNA levels of Lumican and integrin with the SYBR Green Reagent kit (Applied Biosystems, Foster City, CA). GAPDH was used as the endogenous reference. The PCR primers for Lumican were 5 0 -GGATTG GTAAACCTGACCTTCAT-3 0 (forward) and 5 0 -GATAAAC GCAGATACTGCAATGC-3 0 (reverse). The PCR primers for integrin b1 were 
Western blot analysis
Cells were lysed in RIPA buffer containing complete protease and phosphatase inhibitor cocktail (Sigma). The protein concentration of the cell lysates was quantified by a BCA Protein Assay Kit (Pierce, Rockford). The same amount of protein samples were resolved onto 10% SDS-PAGE and then transferred onto PVDF membranes. After blocking with 5% nonfat milk at 378C for 2 hrs, the membranes were incubated in the primary antibodies diluted by TBST buffer at 48C for overnight, following by incubation with the HRP-conjugated secondary antibody for 2-3 hrs at room temperature. GAPDH antibody was used to verify equal protein loading. Finally the protein bands images were captured by a Tanon detection system with ECL reagent (Thermo). The primary antibodies used in the experiments were anti-Lumican 
RNA interference
Lumican siRNA and scrambled siRNA as the control (Santa Cruz, CA) at the final concentration of 100 nmol/L were transfected into CAFs cells with Lipofectamine2000 reagent (Invitrogen, Carlsbad, CA). Human integrin b1 siRNA and scrambled siRNA as negative control were purchased from Shanghai GenePharma Co., Ltd. The integrin b1 siRNA sense was 5 0 -GCCUUCAAUAAAGGAGAAATT-3 0 and antisense was 5 0 -UUUCUCCUUUAUUGAAGGCTT -3 0 . Then the integrin b1 siRNA and negative control were transfected into MKN45 cells using Lipofectamine2000 reagent (Invitrogen, Carlsbad, CA) according to the manufacturer's instructions. Cells were collected for further assay at 24, 48 and 72 after transfection.
Cell proliferation assay
Cell proliferation was evaluated using the Cell Counting Kit-8 (Dojindo, Kumamoto, Japan). The assay is based on the cleavage of the water-soluble tetrazolium salt WST-8 to formazan by cellular mitochondrial dehydrogenases. Expansion in the number of viable gastric cancer cells resulted in an increase in the activity of the mitochondrial dehydrogenases, which leads to the increase in the amount of formazan dye formed. The formazan dye produced by viable cells was quantified by multi-well spectrophotometer (microtiter plate reader) by measuring the absorbance of the dye solution at 440 nm. Cells (2 3 10 3 per well) with or without 1 ng/mL, 10 ng/mL, 100 ng/mL, 1 lg/mL and 10 lg/mL recLumican (R&D systems, Minneapolis) were seeded into 96-well plates in triplicate and incubated for 96 hrs. CCK-8 solution (10 lL) was added into every plate at 0, 24, 48, 72, 96 and the optical density of the solution in each well was measured after 2-4 hrs incubation.
Cell migration assay
Cell migration assays were performed by using 8 lm transwell chambers (Corning Life Science, Acton, MA). Cells were cultured in serum-free RPMI-1640 for 12-16 hrs, and then 1 3 10 5 MKN45 cells with or without 2,000 ng/mL recLumican in 200 lL serum-free medium were seeded into the upper chamber, and 3 3 10 4 CAFs in 800 lL medium containing 10% fetal calf serum (FBS) were added to the lower chamber. For the invasion assay, the insert membranes were coated with diluted matrigel (BD Bioscience, CA). Cells were then stained with 0.1% crystal violet for 30 min, and nonmigrating or non-invading cells were removed from the upper surface of the chambers. Counting of the migrated and invaded cells was facilitated by photographing the membrane.
In vivo tumorigenesis and metastasis
Male BALB/c nude mice at the age of 4 weeks were purchased from the Institute of Zoology, Chinese Academy of Sciences and housed at a specific pathogen-free environment in the Animal Laboratory Unit of Ruijin Hospital, Shanghai Jiaotong University, School of Medicine. CAFs and MKN-45 cells mixed at the ratio of 1:4 in 100 lL PBS were injected subcutaneously and 250 lL PBS were inoculated peritoneally. Tumor length (L) and width (W) were measured weekly and tumor volume was evaluated using the following formula: tumor volume 5LW 2 p/6. Tumor peritoneal metastasis nodules were counted and analyzed after mice being killed. All experiments on animal were given permission by the Committee on Animal Care in Shanghai Jiao Tong University School of Medicine.
Statistical analysis
The experimental results were shown as mean 6 standard deviation (SD). Student's t test, one-way analysis of variance (ANOVA) and Pearson v 2 test were used to analyze the data and the significance level was set at p < 0.05.
Results
Lumican is highly expressed in CAFs in the tumor microenvironment of GC
To elucidate the role of Lumican in human GC, we quantified expression levels and cellular source of Lumican in GC patients. Using qRT-PCR, we found Lumican mRNA expression in GC tissues was markedly higher than in patientmatched non-tumor gastric tissues (Fig. 1a) . To further illustrate which cell component(s) in gastric cancer tissues is (are) responsible for the higher expression of Lumican, we detected Lumican expression by immunofluorescence staining. As shown in Figure 1e , the expression of Lumican was clearly evident in stromal cells of peri-and intra-tumoral areas. CAFs that were identified by a-SMA staining from human gastric cancer tissues expressed more Lumican protein than NFs from adjacent non-cancerous gastric tissues of the same patient. Consistent with the results above, overexpression of Lumican in CAFs was confirmed by qRT-PCR and Western blot. As shown in Figures 1b-1d , Lumican mRNA and protein expression were significantly higher in the CAFs compared to GC cells and the NFs. And owing to the differential glycosylation patterns of Lumican, the molecular weight of the Lumican protein was almost 55 kDa. Taken together, these findings indicate that CAFs produce higher levels of 55 kDa-Lumican in vivo than NFs present in non-cancerous stroma or in gastric cancer cells, and CAFs are one of the main cellular sources for producing 55 kDaLumican in the tumor microenvironment of GC. Table 1 ). In addition, KaplanMeier survival analysis indicated that the survival rate of patients with strong staining of CAF-derived Lumican was significantly lower than that of those with weak staining (p < 0.05, Fig. 1h ). Thus, Lumican expression is up-regulated in gastric CAFs and is associated with GC mortality.
Stromal Lumican promotes GC cell proliferation, migration and invasion
Considering that Lumican is frequently up-regulated in GC, it is conceivable that it acts as a positive regulator of tumorigenesis. To determine whether Lumican secreted by CAFs contributes to GC cells growth and metastasis in a paracrine manner, we established an in vitro co-culture system (Fig.  2c) , in which fibroblasts were indirectly co-cultured with GC cells, separated by a semi-permeable membrane (pore size of 0.6 lm). At the appropriate time point, GC cells were either assayed by way of the CCK8 cell viability reagent or harvested for RNA and/or protein. In addition, we silenced Lumican in CAFs using small interfering RNA. Figures 2a and 2b document that Lumican expression decreased in CAFs transfected with Lumican-siRNA compared with control-scrambled siRNA (siNC). With Lumican expression modification confirmed, we measured cell proliferation and noted that proliferation in both MKN45 1 CAF-siLumican and MGC803 1 CAF-siLumican cells was slower than in negative groups (Figs. 2d and 2f) . Additionally, MKN45 and MGC803 cells treated with purified recombinant Lumican protein grew faster than MKN45 and MGC803 cells alone (Figs. 2e and 2g) . Thus, stromal Lumican promotes GC cell proliferation in vitro.
Using Transwell assays, we further assessed the effects of Lumican secreted by gastric CAFs on tumor cell migration and invasion, which are key determinants of malignant progression and metastasis. After co-incubation of CAF and tumor cells for set times, the membranes of above layer were stained with crystal violet. As shown in Figures 2h and 2i, data support that stromal Lumican enhances GC cell migration and invasion in vitro.
Lumican stimulates cancer cell proliferation, migration and invasion via activation of the FAK signaling pathway
Accumulating evidence suggests that tumor cell proliferation, motility and survival may be regulated by FAK pathway. 21 We measured CAF-derived Lumican and assessed whether it could modulate activation of the FAK signaling pathway in GC cells. The phosphorylation level of FAK Tyr397, Tyr576/ 577 and Tyr925 in MKN45 and MGC803 cells co-cultured with Lumican siRNA-transfected CAFs was lower than in MKN45 and MGC803 cells co-cultured with CAFs transfected with control scrambled siRNA (siNC), respectively. In contrast, MKN45 and MGC803 cells treated with recLumican promoted phosphorylation of FAK Tyr397, Tyr576/577 and Tyr925 (Figs. 3a-3d) . Therefore, stromal Lumican may be involved in the regulation of the FAK signaling pathway. To investigate whether Lumican could regulate cell proliferation, migration and invasion via the FAK signaling pathway, we next evaluated MKN45 cells co-cultured with CAFs or incubated with recLumican during treatment with a FAK inhibitor (PF-228) (10 lM). Western blot and cell proliferation assays indicated that FAK was effectively inhibited (Fig. 3e) . MKN45/ CAFs and MKM45/recLumican cell growth decreased after treatment with PF-228 compared with untreated cells (Fig. 1f) . In addition, after treatment with PF-228, the numbers of migrated (MKN45 (Figs. 3g and 3h) . Together, these in vitro data support that Lumican regulates cell proliferation, migration and invasion via activation of the FAK signaling pathway in human GC cells.
Lumican upregulates phosphorylation of FAK via inducing integrin b1 expression
We next determined how stromal Lumican activated the FAK signaling pathway in GC cells. It is known that FAK can be activated by integrin, relaying signals from extracellular matrix to the intracellular compartment, to regulate cell motility. 22 To demonstrate whether stromal Lumican could promote phosphorylation of FAK via inducing expression of related integrin, we analyzed in MKN45 and MGC803 cells the expression of integrin, including integrin a2, a3, b1, b2, b3 and b6, after co-incubation with CAFs transfected with human Lumican siRNA (siLumican) or with control scrambled siRNA (siNC). Figures 4a-4c demonstrate that the expression of integrin b1 in GC cells (MKN45 and MGC803) co-cultured with CAF-siLumican was significantly decreased in comparison to GC cells co-cultured with CAF-siNC. We also detected whether CAF-derived Lumican "activates" integrin beta1 on the surface of gastric cancer cells using "active conformation-specific" integrin beta1 antibody HUTS-4 clone. 23 As shown in Figures 4b and 4c , the level of active integrin b1 on the surface of GC cells (MKN45 and MGC803) co-cultured with CAF-siLumican was also lower than GC cells co-cultured with CAF-siNC. To further illustrate the role of integrin b1 in mediating activation of the signaling FAK pathway triggered by stromal Lumican, we generated a model of integrin b1-knockdown using siRNA in MKN45 and MGC803 cells (MKN45-siintegrin b1, MGC803-siintegrin b1) (Fig. 4d) , and then detected the phosphorylation of FAK in MKN45-siintegrin b1 and MGC803-siintegrin b1 cells after co-culture with CAFs or incubation with recLumican. As shown in Figures 4e-4h , the phosphorylation level of FAK Tyr397, Tyr576/577 and Tyr925 in MKN45-siintegrin b1 (MGC803-siintegrin b1) 1CAF or MKN45-siintegrin b1 (MGC803-siintegrin b1) 1recLumican was lower than that in control cells respectively.
In addition, integrin b1 knockdown in MKN45 cells significantly inhibited cell proliferation (Fig. 4i) (Figs. 5c and 5f ) than those generated by MKN45 and MGC803 cells mixed with CAFs-siNC. Using IHC, we analyzed the expression of Ki-67 antigen, a cellular marker for proliferation and found that the number of Ki-67 antigenpositive cells was lower in tumors derived from MKN45 and MGC803 cells mixed with CAFs-siLumican than that in tumors derived from MKN45 and MGC803 cells mixed with CAFssiNC (p < 0.05) (Fig. 5g) . Likewise, there were significantly less visible peritoneal nodules in MKN45 1 CAF-siLumcian and MGC803 1 CAF-siLumcian group compared to control group (MKN45 1 CAF-siNC: 12.20 6 1.92; MKN45 1 CAF-siLumcian: 3.80 6 1.30; MKN45 1 CAF-siNC vs. MKN45 1 CAFsiLumcian: p < 0.05; MGC803 1 CAF-siNC: 9.40 6 1.14; MGC803 1 CAF-siLumcian: 5.20 6 1.10; MGC803 1 CAFsiNC vs. MGC803 1 CAF-siLumcian: p < 0.05) (Figs. 5h-5k) . We conclude that Lumican secreted by CAFs promotes tumorigenesis, peritoneal spread and metastasis of GC in vivo.
Discussion
In the tumor microenvironment, the positive and reciprocal interactions between cells and soluble molecules promote tumorigenesis. 24 CAFs are a major constituent of the tumor stroma in many cancers and have been shown to enhance cancer cell proliferation, invasion and angiogenesis 25, 26 via elevated secretion into the tumor microenvironment of multiple chemokines including SDF-1 and CXCL14. 13, 27 However, the mechanisms underlying CAF's promotion of tumor metastasis remain largely unknown in GC. In this study, we identified CAF-derived Lumican, an important member of SLRP family, as an important factor in regulating in cell proliferation and metastatic potential of GC.
Lumican has small core proteins of approximately 40 kDa and possesses 6-10 leucine-rich repeating units which contain four N-glycosylation sites for keratan sulfate/non sulfated lactosaminoglycan chains, the N-terminal bearing cysteine/ disulfide residues and tyrosine sulfate, and the C-terminal domain containing two conserved cysteine residues. 15, 28, 29 Elevated Lumican expression has been observed in pancreatic, colorectal, breast and uterine cervical cancers. [30] [31] [32] [33] However, Lumican may be either positively or negatively correlated with tumor growth. It has been demonstrated in prostate cancer cells that Lumican core protein has no effect on cancer cell proliferation, but impairs migration and invasion. 34 In contrast, Lumican secreted by extracellular matrix can promote colon cancer cell migration through remodeling the actin cytoskeleton. 35 Extracellular Lumican inhibits osteosarcoma cell adhesion through the modulation of TGF-b2 downstream signaling pathways. 36 Not only the differential expression pattern, but also the differing glycosylation patterns of Lumican, may account for Lumican serving in differential roles in vascular invasion, differentiation, proliferation and invasion depending on tissue type. 37 Lumican is not one molecule conserved in all tissues. In this study, we found that Lumican expression was frequently upregulated in GC tissue while primary GC cells and some GC cell lines expressed low levels of Lumican. Our data support that CAFs are the major sources of Lumican in the gastric tumor microenvironment. Moreover, stromal Lumican overexpression predicted late TNM stage and poor survival of patients with GC, which suggests that Lumican may function as an oncogene in GC.
Stromal Lumican secreted from CAFs may exert a paracrine effect on GC cells and contribute to GC progression. Our in vitro data demonstrated a significant decrease or increase in GC cell proliferation, migration and invasion after co-culture with CAF-siLumican or treatment with recombinant Lumican protein respectively. Effect of stromal Lumican on cancer metastasis was further evaluated by co-injecting CAFs-siLumican with GC cells. The significant decrease in the number of metastatic peritoneal nodules suggested the therapeutic potential of targeting stromal Lumican as a new strategy against metastatic GC.
FAK is a cytoplasmic protein tyrosine kinase that is activated by interactions with integrin or growth factor receptors. 38 FAK is known to have a pivotal role in the regulation of cell proliferation, motility and survival in many cell types. 21 FAK activation leads to the auto-phosphorylation of FAK on Tyr397, creating a high affinity binding site for Src homology 2 (SH2) domain-containing proteins. The binding of Src family kinases onto the phospho-Tyr397 of FAK contributes to the promotion of FAK kinase activity and signaling as a result of additional tyrosine phosphorylation at other tyrosine sites, including Tyr407, Tyr576, Tyr577 and Tyr925 of FAK. 22, 39 In our study, we showed that knocking down the expression of CAF-derived Lumican by RNA interference decreased the phosphorylation of FAK in GC cells, indicating that CAF-derived Lumican expression augments phosphorylation levels of FAK in GC cells. Integrin-dependent adhesion and signaling is vital for transmission of a survival signal that instructs the cell to be in the correct location. 40 In the absence of this signal, the cells undergo apoptosis, which is anoikis. FAK plays an important role in the regulation of adhesion responsive signals to proliferate, initiating downstream signaling pathways, involving PI3K/Akt and MAPK, and expression of regulators of proliferation, for example, cyclins. 41, 42 Our data showed that activation of FAK signaling by stromal Lumican promoted gastric cancer cell proliferation and metastatic potential. We speculate that FAK may indirectly contribute to cell proliferation by preventing anoikis via multiple downstream pathways. However, metastatic tumor cells may escape from anoikis, which the underlying mechanism remains largely unknown. FAK can be activated by integrin relaying signals from the extracellular matrix to the intracellular compartment, to regulate cell adhesion and motility. 22 Other has demonstrated that the integrin b1-FAK signaling axis plays a critical role in controlling the initial proliferation of micrometastatic cancer cells disseminated in the lungs. 43 In this study, we found that GC cells co-cultured with CAFs-siLumican expressed relatively lower levels of active integrin b1, which suggests that stromal Lumican may promote phosphorylation of FAK via inducing expression and functional activation of integrin b1. Silencing the expression of integrin b1 in GC cells suppresses the phosphorylation of FAK induced by stromal Lumican. The evidence supports that integrin b1 plays an essential role in enabling the activation of the FAK pathway, which appears to explain how stromal Lumican secreted by CAFs contributes to the progression of GC.
In summary, we have demonstrated that stromal Lumican overexpression predicted late TNM stage and poor survival in human GC, and that CAF-derived Lumican regulated GC cell proliferation, migration and invasion by activation of the integrin b1-FAK pathway. These findings shed light on the mechanism of CAF-derived Lumican in the progression of human GC and highlight this pathway as a therapeutic target in the treatment of GC.
